Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Spain

EE252

Gibson S, Behncke J, Buseghin G, Unzalu A, Luca T, Gomez J
Olympus Europa SE & Co. KG, Hamburg, Germany

Background

- Benign prostatic hyperplasia (BPH) is a progressive, non-malignant enlargement of the prostate common in men over 50.[1]
- BPH may cause lower urinary tract symptoms (LUTS) which can have a major negative impact on quality of life.[2]
- Despite the advancement of minimally invasive surgical therapies (MISTs), transurethral resection of the prostate (TURP) remains the gold standard for the surgical management of LUTS for patients either failing or refusing medical therapy.[3]
- The temporary implanted nitinol device (iTind; Olympus Corporation, Tokyo, Japan), which is placed into the prostatic urethra with the aim of reshaping the tissue of the prostatic urethra and the bladder neck, is a minimally invasive treatment option to deliver rapid and effective symptomatic relief from BPH symptoms.[4,5]
- Within the context of an increasingly ageing population as well as backlogs and delays in elective urological procedures caused by the coronavirus disease 2019 pandemic, healthcare systems and societies face a considerable and growing burden associated with managing the condition.[1,6]

Figure 1. Budget impact model structure



AE: adverse event; BPH: benign prostatic hyperplasia; HCP: healthcare professional; LUTS: lower urinary tract symptoms; TURP: transurethral resection of the prostate.

Figure 2. Disaggregated cost per procedure



AE: adverse event; TURP: transurethral resection of the prostate.
Note that the relative size of each bubble proportionally reflects the cost of each disaggregated cost element. Pre-procedure components include pathology costs and healthcare professional time required ahead of the procedure. Procedure cost components include consumables, and HCP and facility costs for. Post-procedure cost components reflect only HCP and facility time required following the procedure. AE components represent the average cost of managing complications associated with each procedure.

Figure 4. One-way sensitivity analysis for budget impact of iTind



AE: adverse event; TURP: transurethral resection of the prostate.

Acknowledgements: The authors would like to thank Jamie Harding at Olympus UK & Ireland, for poster design assistance.

Presented at ISPOR Europe 2022 | Vienna, Austria | 6-9 November 2022.

Objective

- To estimate the cost and resource impact of iTind as a minimally invasive treatment alternative to TURP for the treatment of LUTS associated with BPH in Spain.

Methods

Model Structure

- An Excel-based budget impact model was developed to estimate the economic impact of introducing iTind in a Spanish National Health System (NHS) setting.
- The model compared two scenarios; a reference case where all patients received either bipolar or monopolar TURP, and a scenario where a proportion of patients received iTind rather than TURP (**Figure 1**).
- Reference case data were based on a 2018 national hospital database cohort of 1,195 BPH patients with LUTS who received a TURP from one of 20 Spanish hospitals.[7]

Market Dynamics

- In the TURP scenario, all patients received either bipolar (30%) or monopolar (70%) TURP.
- In the TURP and iTind scenario, 7.5% of patients received iTind rather than TURP and this came from bipolar and monopolar procedures proportionally.
- Market dynamics inputs were based on Spanish expert opinion.

Resource Use Inputs

- Modeled costs included the per procedure cost of consumables, pathology, healthcare professional (HCP) time, facility costs, and managing adverse events (AEs).
- Where available, pathology, HCP time, facility costs, and AE management costs were identified from a Spanish hospital cost database (Red Española de Costes Hospitalarios), based on Spanish ICD-10 codes.
- Consumables, HCP time, and AE management costs were extracted from relevant scientific literature following a pragmatic literature search and inflation adjusted to 2021 values.

Outputs

- The primary model output was the total budget impact.
- Secondary model outputs included budget impact per person, average total and disaggregated per procedure costs, and per procedure resource utilization.

Sensitivity Analysis

- A one-way sensitivity analysis, which varied each input by ± 20% to determine which variables had the greatest impact on model results, was performed.

Budget Impact Results

- The total calculated costs of TURP and iTind procedures in Spain were 3,780 EUR and 2,739 EUR, respectively (**Figure 2**; disaggregated per procedure costs also shown).
- Total budget impact of treating 7.5% (90) of patients with iTind rather than TURP was -93,260 EUR (a 2.1% reduction in the total cost of care).
- Average budget impact per person was -78 EUR.
- In terms of resource utilization (**Figure 3**), 67 hours of operating room time, 488 hours of healthcare professional (urologists, anesthesiologists, nurses, and support staff) time, and 345 post-operative hospital bed days were saved in the scenario with iTind (4.5%, 5.3%, and 7.5% reductions, respectively).

Figure 3. Disaggregated resource utilization per procedure



TURP: transurethral resection of the prostate.
**Note that the axis of this figure does not extend to show the full hospital bed stay incurred by patients receiving TURP (3.85 days).*

Sensitivity Analysis

- The total budget impact was most sensitive to changes in the price of the iTind device, followed by the operating cost of hospital resources (operating room and hospital bed costs), and AE management (surgical retreatment rate and the cost of managing clot retention) (**Figure 4**).

Limitations

- The model retrospectively analyzed a static cohort of patients who received a TURP procedure, underestimating the burden of LUTS associated with BPH in Spain which could be managed with iTind.
- Other patient groups (e.g., patients receiving medical therapy) that would benefit from an iTind procedure were excluded from this analysis.
- The model assumes that the iTind procedure was performed in an inpatient setting, but given there is no requirement for general anesthesia, the iTind procedure could be performed in an office setting.[4,5]
- The model utilized inputs and assumptions to estimate the budget impact from a Spanish NHS perspective, but the generalizability to specific hospitals with different costs or treatment options (e.g., no bipolar TURP or alternative MISTs offered) may differ.

Conclusions

- Adopting iTind in clinical practice for eligible patients is a cost- and resource-saving approach to managing LUTS associated with BPH.

References

1. María Molero J, Miñana B, Palacios-Moreno JM, et al. Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain. Int J Clin Pract. Nov 2020;74(11):e13602. doi:10.1111/ijcp.13602
2. Kaur D, Massaon HK, Singh H, Kaur M. To Assess the Quality of Life in Patients with Benign Prostate Hyperplasia (BPH) Based on Urinary Symptoms. Journal of Clinical and Diagnostic Research. March 2020;14(3)(BC01-BC04)doi: 10.7860/JCDR/2020/42944.13542
3. Nickel JC, Méndez-Probst CE, Whelan TF, Paterson RF, Razvi H. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. Oct 2010;4(5):310-6. doi:10.5489/cuaj.10124
4. Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. Jun 2021;24(2):349-357. doi:10.1038/s41391-020-00281-5
5. Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology. Jul 2021;153:270-276. doi:10.1016/j.urology.2020.12.022
6. Uimonen M, Kuitunen I, Seikkula H, Mattila VM, Ponkilainen V. Healthcare lockdown resulted in a treatment backlog in elective urological surgery during COVID-19. BJU Int. Jul 2021;128(1):33-35. doi:10.1111/bju.15433
7. Red Española de Costes Hospitalarios. Accessed 20 June 2022, https://www.rechosp.org/faces/es/jsf/index.jsp